CervoMed Announces Pharmacokinetic Results with New Neflamapimod Oral Tablet Formulation and Secures FDA Removal of Drug ...
New 50 mg tablet formulation delivers an improved pharmacokinetic profile and enables greater exposure and patient convenience FDA removal of the prior drug exposure limit provides greater dosing flexibility in future clinical trials CervoMed plans to …